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Viral infection of the cell is able to initiate a signaling cascade of events that ultimately attempts to limit viral
replication and prevent escalating infection through expression of host antiviral proteins. Recent work has
highlighted the importance of the host antiviral protein viperin in this process, with its ability to limit a large
variety of viral infections as well as play a role in the production of type I interferon and the modulation of a
number of transcription factor binding sites. Viperin appears to have the ability to modulate varying conditions
within the cell and to interfere with proviral host proteins in its attempts to create an unfavorable environment
for viral replication. The study of the mechanistic actions of viperin has come a long way in recent years,
describing important functional domains of the protein for its antiviral and immunemodulator actions as well as
demonstrating its role as a member of the radical SAM enzyme family. However, despite the rapid expansion
of knowledge regarding the functions of this highly conserved and ancient antiviral protein, there still remains
large gaps in our understanding of the precise mechanisms at play for viperin to exert such a wide variety of
roles within the cell.
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Viral infection of mammalian cells results in activa-
tion of a number of viral recognition pathways triggered
by replication intermediates and or viral proteins,
which ultimately induce innate defenses to limit viral
replication [1]. Pivotal to this antiviral response is the
induction of interferon (IFN). There are three types of
IFN, type I IFNs (IFN-α and IFN-β), type II IFN (IFN-γ)
and type III IFNs (IFN-λ1, IFN-λ2 and IFN-λ3). The
type I IFNs are essential for immune defenses against
viruses and, following binding to the type I IFN
receptor, induce the expression of hundreds of
interferon-stimulated genes (ISGs), many of which
act to limit viral replication. The importanceof this early
IFN response to viral infection is highlighted by the fact
that most viruses have evolved strategies to combat
either IFN production or IFN action [2]. Despite our
increasing knowledge of the host's response to viral
infection, the role of most ISGs remains elusive, anduthors. Published by Elsevier Ltd.
ccess under CC BY-NC-ND license.only a handful of antiviral host effectors have been
described in the literature. Viperin is one of the few
ISGs shown to have direct antiviral activity and has
received increasing attention due to its ability to limit a
broad range of viruses and play an emerging role in
modulating innate immune signaling. Here we review
the literature surrounding the spectrum of viruses for
which viperin has antiviral activity.Structure and Characterization
Viperin (also known as cig5 and RSAD2) is a
highly species conserved, 361-amino-acid protein
with a predicted molecular mass of 42 kDa. It was
first identified as a human cytomegalovirus (HCMV)-
inducible gene in fibroblasts, where two cDNA frag-
ments termed cig5 and cig33 were later found to form
the one transcript that was renamed viperin [for
virus inhibitory protein, endoplasmic reticulum (ER)J. Mol. Biol. (2014) 426, 1210–1219
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expressed by a wide variety of mammals and fish and
has been more recently demonstrated in reptiles. It is
composed of three distinct domains: an N-terminal
domain that varies considerably between species and
contains both an amphipathic helix and a leucineFig. 1. Viperin is highly conserved. (a) Viperin homology a
conserved domains including the radical S-adenosyl methionin
The C-terminal region of viperin is also highly conserved and
replication of a number of viruses.zipper domain, a highly conserved central domain
containing a “radical SAM domain” and a C-terminal
domain that shows striking similarity across species
and has recently been shown to be critical for viperin's
antiviral properties against a number of viruses
(Fig. 1). The amphipathic helix is located from residuecross multiple species. (b) Viperin contains a number of
e (SAM), a leucine zipper domain and an amphipathic helix.
has been demonstrated to be critical for its ability to limit
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mediates viperin's ability to bind to the cytosolic face
of the ER, as well as its association with lipid droplets
[5,6]. The central domain of the protein (residues 71–
182) carries 4 motifs characteristic of members of the
radical SAM (S-adenosyl-L-methionine) enzymes, with
motif 1 containing a CxxxCxxC sequence responsible
for binding iron sulfur clusters. Recent work has been
able to demonstrate that viperin can bind FeS clusters
and reduce S-adenosyl-L-methionine to 5′deoxyade-
nosine, a characteristic function of radical SAM
enzymes [7,8]; however, no enzymatic function has
been assigned to viperin as yet, although this domain
has been shown to be important in viperins ability to
limit both human immunodeficiency virus (HIV) and
Bunyamwera virus [9,10] and in the ability of HCMV to
co-opt viperin as a proviral host protein (discussed
below) [11]. The C-terminal domain of viperin is highly
conserved, and its presence is critical for its antiviral
function against the Flaviviridae members hepatitis C
virus (HCV) and dengue virus (DENV); however, its
exact role still remains unknown [5,12].Viperin Regulation
Viperin is expressed in most cell types at very low
basal levels and has been demonstrated to be induced
by type I IFN, type II IFN, type III IFN, double-stranded
DNA, double-stranded RNA (dsRNA) analogues, LPS
and multiple viruses. Viperin induction through classi-
cal IFN pathways has been demonstrated via stimula-
tion with LPS, double-stranded DNA, poly I:C and
multiple viruses, includingPseudorabies,Sendai virus,
Sindbis virus and lymphocytic choriomeningitis virus
[11,13–16]; all of which bind to and activate pattern
recognition receptors such as Toll-like receptors TLR3
and TLR4, the cytosolic retinoic acid-inducible gene
I-like receptors (RLRs) and cytosolic DNA sensors.
These in turn are able to activate interferon regulatory
factors IRF3 and IRF7 to produce IFN-β, which is able
to act in both a paracrine manner and an autocrine
manner to bind the cell surface type I IFN receptor
and initiate a signaling cascade that culminates in the
formation of the ISG factor 3 (ISGF3), which is able
to bind the viperin promoter and induce expression.
Viperin has been previously demonstrated to be very
tightly regulated by ISGF3, with counter-regulation
exerted by the PRDI-binding factor-1 (BLIMP-1) [15];
however, more recent work by Xu et al. has indicated
that the transcription factor promyelocytic leukemia
zinc finger protein (PLZF) is essential for IFN-regulated
viperin expression [17]. IFN stimulates an association
of PLZF with promyelocytic leukemia protein and
histone deacetylase 1 to induce a specific subset of
ISGs, including viperin. Mice deficient for PLZF were
unable to efficiently upregulate viperin and other key
antiviral effectors upon IFN-α stimulation and, conse-
quently, were more susceptible to viral infection [17].Viperin can also be upregulated independently of
IFN, through an IRF1 or IRF3 mechanism [18–20],
and a number of viruses, including HCMV, vesicular
stomatitis virus, Japanese encephalitis virus (JEV)
and Chikungunya virus (CHIKV), can induce viperin
independently of IFN production [3,13,16,21]. Follow-
ing viral dsRNA stimulation of RLRs, they interact with
the adaptor protein MAVS (mitochondria-associated
adaptor molecule, also termed Cardif, IPS-1 or VISA)
to promote the expression of IFN-β and, conse-
quently, ISGs. MAVS is now known to reside on both
the peroxisomeand themitochondrialmembrane, and
it is the initial activation of peroxisomal MAVS by viral
stimulated RLRs that results in rapid and transient
induction of some ISGs, including viperin through
an IRF1- and IRF3-dependent gene induction [22].
In contrast, mitochondrial MAVS activates an IFN-
dependent induction of viperin and other ISGs to
set up a stable antiviral environment within the cell.
Therefore, viperin IFN-dependent expression is
mediated by ISGF3 and PLZF, whereas its IFN-
independent expression is controlled via IRF1 and
IRF3.Antiviral Functions of Viperin In Vitro
Viperinwas first shown to be antiviral against HCMV,
where overexpression of viperin in human fibroblasts
prior to HCMV infection was found to significantly
decrease expression of the late viral proteins gB, pp28
and pp65 [3]. Viperin has since been demonstrated
in vitro to have antiviral activity against a broad range
of viruses from both DNA and RNA viral families;
however, the full elucidation of antiviral mechanisms at
play still remains somewhat elusive (Table 1).
Viperin expression has been shown to inhibit both
influenza A and HIV-1 through blocking viral particle
release [9,26,27]. HeLa cells overexpressing either
murine or human viperin have been shown to inhibit
viral budding from the plasma membrane by disrupt-
ing lipid rafts and increasingmembrane fluidity [26,27]
(see Fig. 2). In this instance, viperin was found to
bind farnesyl diphosphate synthase (FPPS), a critical
enzyme in the mevalonate pathway, which is involved
mainly in cholesterol and sterol biosynthesis, protein
farnesylation and geranylgeranylation. The effect of
viperin on influenza budding from the plasma mem-
branes was reversed via overexpression of FPPS,
substantiating its importance in the viral budding of
influenza from the plasma membrane; however, the
precise mechanism by which viperin affects mem-
brane fluidity and disrupts lipid rafts was unable to be
determined [27]. In parallel, viperin overexpression in
HEK293 cells is also able to inhibit HIV-1 egress from
the cell, and this was found to be dependent on the
enzymatic domain (SAM domain) of viperin [9]. HIV-1
infection of primary monocyte-derived macrophages
(MDMs) was found to induce viperin and redistribute it
Table 1. Critical antiviral domains of viperin
Virus Mechanism Critical domains Ref.
RSV nd nd [39]
DENV Inhibits replication via interaction with DENV NS3 C′-terminus [12,32]
HCV Inhibits replication via localization in RC with
HCV NS5A and VAP-A
C′-terminus and amphipathic helix [28,33]
CHIKV nd Amphipathic helix [36]
Influenza A Inhibits viral budding from the plasma membrane,
possibly via interacting with FPPS
nd [26,27]
HIV Inhibits viral egress SAM domain [9]
Bunyamwera virus Inhibits replication SAM domain [10]
WNV nd nd [31]
Sindbis virus nd nd [23]
HCMV nd nd [3]
Rhinovirus nd nd [24]
HCMV nd nd [3]
Vesicular stomatitis virus nd nd [25]
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α-treated MDMs) into foci containing p24 and CD81,
a marker for the site of HIV-1 viral assembly and
accumulation. Interestingly, the addition of exogenous
farnesol was also able to increase HIV-1 cDNA
levels, indicating that, in this infection system, viperin's
interactionwith FPPSmayalsobe inhibitingHIV-1 viral
egress, although this still needs to be validated [9].Fig. 2. Viperin acts as both an antiviral and a proviral host pr
cycle; it has been demonstrated to associate with the RCs of b
protein 5A (NS5A) and NS3, respectively. In the case of HCV
VAP-A. Viperin is also able to limit viral egress of both HIV an
respectively, although themechanism surrounding this remains e
as a proviral host factor, by trafficking it to the mitochondria attac
protein (vMIA) where it is able to bind HADHB and cause disrupViperin also inhibits members of the Flaviviridae
family of viruses, withHCV,DENVandWestNile virus
(WNV) all restricted by viperin in vitro [5,12,28–32].
With the use of a HEK293 HCV replicon-based
system, with viperin under the transcriptional control
of tetracycline, the protein was shown to impede HCV
replication. In this model system, the radical SAM
domain and the C-terminal residue were found to beotein. Viperin is able to act at multiple stages of the viral life
oth HCV and DENV, by interacting with the non-structural
NS5A, viperin also associates with the proviral host factor
d influenza through the plasma membrane and lipid rafts,
lusive. HCMVhas also been demonstrated to co-opt viperin
hed to the viral mitochondria-localized inhibitor of apoptosis
tion of the cytoskeleton, thereby increasing viral entry.
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the N-terminal region containing the amphipathic helix
was found to be dispensable [29]. Further work by two
groups looking at the ability of viperin to limit HCV
in the more physiological setting of the complete
HCV life cycle in hepatocyte cell lines was able to
demonstrate that theC-terminal domainwas essential
for viperin to limit HCV in vitro; however, the radical
SAM domain was not required [5,33]. The N-terminal
amphipathic helix was also shown to be important for
viperin's ability to bindand interactwith theHCVNS5A
protein on the lipid droplet surface and within the
replication complex (RC) of HCV, both of which were
required for viperin to impart its antiviral activities [5].
Viperin was also shown to interact with the proviral
host factor, vesicle-associated membrane protein-
associated protein-A (VAP-A) in RCs, and impair
its association with NS5A, which is critical for HCV
replication [5,33].
Utilizing the same HEK293-inducible cell lines as
mentioned above for HCV, we also showed viperin
expression to limit both DENV-1 and WNV using a
virus-like particle/replicon system, and once again,
the radical SAM domain was shown to be critical
[30]. More recently, with the use of an infectious
cell culture model, viperin was shown to be antiviral
against DENV-2 in Huh-7, A549 and primary human
MDMs [12]. Viperin was shown to impede early RNA
replication and co-localized and co-precipitated
with dsRNA in DENV-2-infected cells, suggesting a
possible interaction of viperin at sites of DENV-2
replication. Viperin was also shown to interact with
DENV-2 NS3 (protease/helicase) protein, which is
essential for replication, and this interaction was crucial
for its antiviral activities andmediatedby theC-terminus
of the protein. In contrast to previous reports, in using
the DENV-2 infectious system, neither the N-terminal
amphipathic helix nor the radical SAMdomainof viperin
was found to be important in its ability to limit DENV-2
replication,which either highlights a difference between
viperin's ability to restrict DENV-1 and DENV-2 or
perhaps displays the importance of performing these
studies in physiologically relevant cell culture systems
that harbor the complete virus life cycle.
Viperin has also been shown to interactwithDENV-2
capsid protein and HCV core on the surface of lipid
droplets, a cellular organelle that is hypothesized to be
a scaffold for viral assembly [5,12]. In the case of
DENV-2, the lossof theN-terminal amphipathic helix of
viperin, which mediates its association with both the
ER and lipid droplets, abrogated its anti-DENV activity,
indicating that its association with the capsid protein
is not its main mechanism for limiting DENV viral
replication. In parallel, the amphipathic helix of viperin
was required for its ability to restrict HCV replication, as
well as its ability to interactwithHCVcoreandNS5Aon
the surface of the lipid droplet and with NS5A within
putative RCs. As mentioned above, viperin's asso-
ciation with NS5A and VAP-A in the HCV RC wasdemonstrated tomediate its anti-HCVeffects, and one
plausible explanation is that the association seen
between HCV core and viperin on the surface of the
lipid droplet is in fact due to the ability of NS5A and
HCV core to still co-localize at this site while NS5A is
associated with viperin [34].
The amphipathic helix of viperin is required for its
association with the ER and its ability to localize to
lipid droplets [5,6,35]. Its presence is essential for its
anti-HCV activities and its ability to bind and localize
in the RC with HCV NS5A; however, it is dispensable
for its anti-DENV activities and its association with
DENV NS3, perhaps due to the varied distribution of
DENV NS3 during infection. Viperin's amphipathic
helix is also essential for its ability to limit CHIKV [36].
CHIKV was found to co-localize with viperin in the ER
of HEK293 cells, and CHIKV nsP2 (an RNA helicase/
protease that mediates replication) was found to also
localize to the periphery of the ER with significantly
reduced levels observed during viperin overexpres-
sion. CHIKV nsP2 is known to interact with many host
proteins in the ER to facilitate replication; however, it is
unknown whether viperin's inhibitory effect on nsP2 is
direct or indirect [36,37].In Vivo Antiviral Functions of Viperin
Studies translating the antiviral activity of viperin in
cell culture to its function in an in vivomodel havebeen
somewhat lacking, most likely reflecting redundancy
in the innate antiviral response in which the absence
of viperin can be compensated by other ISGs resulting
in mice that can still respond to a viral infection. This is
certainly the case with influenza virus (IFV) in which
ectopic viperin expression inHeLa cells can inhibit IFV
release from the plasma membrane by affecting the
formation of lipid rafts and direct interaction with the
FPPS, an enzyme essential for isoprenoid biosynth-
esis (as discussed previously). However, this in vitro
observation did not translate to a mouse model of IFV
infection using viperin knockout mice in which no
difference was observed in susceptibility, pulmonary
damage or IFV titers between wild type (WT) and
viperin−/−mice [26]. This discrepancymay be due to a
number of factors. As suggested above, redundancy
in the ISG innate response may contribute and,
together with the acute nature of infection and its
ability to block the host innate immune signaling, may
suggest that IFV can overcome the antiviral nature
of viperin. Interestingly, viperin expression peaked at
5 days post infection, after which IFV infection is well
established.
In contrast to the experience with IFV, viperin has
recently been shown to restrict the replication of both
WNV and CHIKV in mouse models [31,36]. In contrast
to WT mice, mice deficient for viperin expression
succumbed to subcutaneous injection of WNV and, in
the case of CHIKV, had higher viremia and more
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antiviral effect was noted predominantly in the CNS
and direct intracranial injection of WNV resulted in
regional differences in WNV titers between WT and
viperin−/− mice [31]. Notably, increased WNV titers
were seen in the cortex, spinal cord and white matter
in viperin−/− mice and it was suggested that the
antiviral function of viperin may restrict the spread and
infection of neuronal subsets. This was confirmed in a
follow-up study revealing that different neuronal
subtypes have distinct antiviral IFN responses [38].
Notably, granule cell neurons were more resistant
to WNV infection compared to cortical neurons a
function that was attributed to expression of a subset
of ISGs, one of which was viperin [38]. In fact, cortical
neurons could be made resistant to WNV infection
after ectopic expression of viperin, while in the mouse
brain, granule cell neurons were less vulnerable to
WNV infection compared to cortical neurons. Impor-
tantly, in human brain tissue infected with WNV,
granule cell neuronswere relatively spared fromWNV
infection compared to other neuronal populations.
Clearly different cell types evenwithin the same tissue
can express different ISG programs that may confer
resistance to viral infection.
Infection with CHIKV virus causes a very different
pathology from that of WNV in that there is generally
no CNS involvement with patients developing an
incapacitating arthralgia during the acute phase with
symptoms usually resolved within 7–10 days; how-
ever, in some patients, symptoms can last for many
months to years. Patients infected with CHIKV show
a strong IFN response that often correlates with the
level of viremia and significant corresponding ISG
expression, including viperin in PBMCs [36]. While
viperin was shown to restrict CHIKV replication in vitro,
its importance as a host antiviral ISGwas confirmed by
in vivo CHIKV infection of viperin−/− knockout mice.
Loss of viperin expression resulted in a significant
increase in CHIKV viremia, and while loss of viperin
had no impact on mortality of the mice, it resulted in
increased disease susceptibility and joint inflammation
[36]. Combining the observations from human studies
and the ability of viperin to restrict CHIKV replication
in vitro and in vivo, it was proposed that viperin
expression induced early as a result of activation of the
innate arm of the immune response can limit CHIKV
replication and the accompanying inflammation. It will
be interesting to determine in humans the spectrum
of viperin expression in individuals that have mild
compared to those that have protracted disease
and the existence of viperin polymorphisms that may
impact disease severity.
The only study to date to analyze the ectopic
expression of viperin in vivo was performed in the
context of respiratory syncytial virus (RSV) change
of the chinchilla airway [39]. Viperin expression was
found to be significantly upregulated in the naso-
pharynx of the chinchilla up to 7 days post RSVchallenge, and the pre-infection delivery of a recom-
binant adenoviral associated vector was able to
further increase viperin expression in the nasophar-
ynx by up to 51%. This increased viperin expression
was able to significantly reduce viral titers of RSV in
nasopharyngeal lavage fluid by approximately 1 log at
7 days post infection [39]. This study highlights the
importance of viperin as an antiviral at the mucosal
barrier and potentially underpins the possibility for the
use of a viperin mimic in therapeutic situations in the
distant future.Viperin and Modulation of
Immune Signaling
While there is clear evidence that viperin has
antiviral activity against a diverse group of pathogens,
it is emerging that viperin may also contribute to
immune signaling. This was first identified in mice
deficient for viperin (viperin−/−) expression that exhib-
ited no significant phenotypic changes; however,
challenge of these mice with ovalbumin (OVA) that
induces a mixed Th1/Th2 response resulted in a
significant reduction in OVA-specific IgG1 suggesting
that viperin may be involved in regulating the Th2
response [40]. Consistent with this observation,
stimulation of T cells from viperin−/− mice with anti-
CD3/CD28 resulted in a significant decrease in the
expression of Th2 cytokines IL-4, IL-5 and IL-13
compared to WT T cells. This decrease was attributed
to a defect in the induction of GATA-3 (a well-
characterized regulator of Th1/Th2 differentiation)
and decreased DNA binding activities of NF-κB/p50
and AP-1. The authors concluded that viperin was
crucial for T cell activation and differentiation; however,
no mechanism was provided and it will be interesting
to determine if similar findings will be seen in in vivo
Th2-associated disease models.
Not only does viperin posses direct acting antiviral
activity but recent data suggest that it may impact
innate antiviral signaling. Viperin can modulate TLR7
and TLR9 recognition of viral nucleic acids in pDCs
to promote type I IFN production [41] (see Fig. 3).
Type I IFN production is crucial in the host response
and control of viral infections through inducing the
expression of antiviral effector genes and modulation
of the adaptive immune system. Saitoh and collea-
gues showed that pDCs deficient for viperin were also
deficient in type I IFN production in response to TLR7
and TLR9 ligands. This effect was dependent on the
N-terminal amphipathic helix of viperin that anchors it
to the lipid droplet and mediates signaling from TLR7
and TLR9. Specifically, viperin was found to recruit
the adaptor molecules IRAK1 and TRAF6 to the
lipid droplet to facilitate the ubiquitination of IRAK1 by
TRAF6 that, in turn, results in nuclear translocation
of IRF7 to the nucleus and stimulation of type I
IFN expression. Consistent with the abovementioned
Fig. 3. Viperin is required for TLR7/TLR9 activation in pDCs. Viperin is essential for activation of TLR7 and TLR9 and the
subsequent downstream upregulation of type I ISGs. Following activation of TLR7/TLR9 by single-stranded RNA (ssRNA) or
CpG, myeloid differentiation primary response gene 88 (MyD88) is able to mediate the TLR7/TLR9 signals to lipid bodies.
Viperin then interacts with the signal mediators, interleukin-1 receptor-associated kinase 1 (IRAK1) and TNF receptor-
associated factor 6 (TRAF6) to recruit them to the lipid bodies and facilitate K63-linked ubiquitination of IRAK1 to induce the
nuclear translocation of transcription factor IRF7 and subsequent upregulation IFN-regulated gene transcription.
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was recently demonstrated that knockdown of viperin
reduces CD40-ligand-mediated activation of NF-κB in
carcinoma cells and downstream recruitment of IRF7
to the nucleus resulting in a decrease in IFN-β gene
expression [42]. Thus, it is becoming clear that not
only does viperin play a direct role in attenuating viral
infection but it also augments innate immune signaling
and thus it may contribute to the host antiviral
response on multiple fronts.Escape and Utilization of Viperin
by Viruses
Viruses have evolved multiple mechanisms to
combat varying arms of the host innate immunesystem, including evasion of antiviral host proteins,
with PKRbeing an excellent example [43,44]. To date,
two viruses, JEV and HCMV, have been reported to
evade the antiviral properties of viperin, with the later
actually co-opting viperin to its advantage [11,13]. In
contrast to other plus-strand viruses such as HCV and
WNV, overexpression of viperin was not found to
have an impact on JEV replication and, moreover,
JEV does not replicate to increased titers in cells
depleted of viperin; however, JEV is able to directly
induce viperin in an IFN-independent manner [13].
With the use of A549 cells, induction of viperin by JEV
can only be seen in the presence of the proteasome
inhibitor MG132, suggesting that JEV is negatively
controlling viperin protein expression to circumvent its
antiviral effects; however, no mechanism was deter-
mined for this degradation [13].
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viperin expression in vitro when it is expressed in the
cell prior to infection [3]. However, when human
fibroblasts cells were infected with HCMV, the virus
induced viperin expression that localized to the
ER after 24 h, but at day 3 post infection, viperin
relocalized to the Golgi and to unidentified cytoplas-
mic vesicles where it co-stained with the viral
envelope protein, gB [3]. This was originally thought
to be a viral evasion mechanism, but it is now known
that the virus transports viperin to the mitochondria
before it relocalizes it to the assembly compartment
as a strategy to enhance viral infection through actin
cytoskeleton disruption [11]. The HCMV viral protein,
vMIA (viral mitochondrial inhibitor of apoptosis) was
found to interact with viperin and relocate it to the
mitochondria, where it was able to interact with the
β subunit of the mitochondrial trifunctional protein
(TFP), a protein that mediates β-oxidation of fatty
acids to generate adenosine triphosphate; this inter-
action causes inhibition of TFP and, subsequently, a
decrease in cellular adenosine triphosphate levels
[11]. The main consequence of viperins' interaction
with TFP was the disruption of the actin cytoskeleton
that served to increase viral infection, and this was
found to be mediated by the radical SAM domain of
viperin (Fig. 2). Interestingly, a similar effect was also
observed when the N-terminal amphipathic helix of
viperin was replaced with a mitochondrial targeting
sequence, indicating that these effects weremediated
directly by viperin itself and that the involvement
of HCMV vMIA is simply to transport viperin to the
mitochondria [11].Biological Mechanisms of Viperin Action
Viperin has been shown to play a role in innate
immunesignaling, to limit varying viruses throughboth
direct inhibition of replication and interference with
viral budding/release and to disrupt the actin cytoske-
leton to increase infectivity of HCMV in an example of
evolutionary escape of HCMV from the antiviral
properties of viperin. Viperin has been shown to bind
the five host proteins FPPS, TFP, IRAK1, VAP-A and
TRAF6 and the three viral proteins DENV NS3, HCV
NS5A and HCMV vMIA in order to accomplish this list
of biological functions. It is unusual for viperin to be
able to interact with such a divergent range of other
proteins and to potentially mediate quite distinct
cellular functions. The extreme C-terminal region of
the protein has been demonstrated to be important for
protein dimerization and in binding HCV NS5A,
VAP-A and DENV NS3 [5,6,12,33]; however, its
function in binding the other mentioned interacting
partners has not been assessed to date andmay shed
further light on the broad biological functions of this
protein. Interestingly, recent studies on the evolution
of primate viperin over some 60 million years showthat it has evolved under positive selection pressure
similar to other antiviral proteins such as PKR [45,46]
and that the C-terminus of viperin displays significant
positive selection. The structural regions of viperin
under the highest positive selection were found to
be the middle region (immediately following the
N-terminal amphipathic helix), the radical SAM
domain and the C-terminus, in particular, the
C-terminal amino acid. This pattern of dispersion of
residues is similar to that seen for PKR and demon-
strates escape from viral antagonism over the course
of primate evolution, highlighting regions of importance
within the protein.
The ability of viperin to bind to the cytosolic face of
the ER has also been associated with its capacity to
inhibit secretion of soluble proteins and reduce the
rate of ER-to-Golgi traffic, as well as induce heigh-
tenedmembrane curvature of the ER [6]. It is plausible
that this property of viperinmay inhibit the trafficking of
viral andhost proteins required for replication, budding
and egress or potentially interferewith the formation of
ERmembranous complexes required for the life cycle
of some viruses. However, in the case of HCV, this
does not appear to be the case. HCVRCs are derived
from the ER and form the platform for viral replication
within the cell; viperin was found to localize to these
RCs in conjunction with NS5A and the proviral host
factor VAP-A but did not limit the number or spatial
distribution of RCs in a cell (K.J.H. and M.R.B.,
unpublished results); however, further work remains
to be done to ascertain the functionality of these RCs
[5,47].
The ER in conjunction with the Golgi is also an
important site for the synthesis of bulk lipids and
cholesterol, both of which are important components
for viral entry, assembly and budding, not only in the
context of lipid raft formation but also in the context of
viral replication for somemembers of the Flaviviridae
family of viruses. Cholesterol and lipids must be
transported from the ER to other organelles, such as
endosomes, mitochondria and plasma membranes;
the ER resident protein, VAP-A, is an important protein
implicated in these processes along with oxysterol-
binding protein (OSBP) [48]. Viperin is able to interact
with VAP-A, and it is possible that this association
may underpin its ability to limit multiple viruses
[5,33]. Recent work has shown that the ISG IFITM3
(interferon-inducible transmembrane protein-3) is
able to also bind VAP-A and, in doing so, inhibits its
ability to interact with OSBP and consequently alters
the balance of cholesterol in late endosomes, inhibit-
ing viral egress into the cytosol [49]. IFITM3 is a
transmembrane protein, and its ability to bind VAP-A
will have localized effects; however, viperin has been
demonstrated to reside in the ER, as well as piggy-
back with viral proteins, such as HCMV vMIA to the
mitochondria and HCV NS5A and DENVNS3 to sites
of replication [5,11,12]. It is possible that viperin may
indeed contribute to an alteration in cholesterol or lipid
1218 Review: The Role of Viperin in Antiviral Response.homeostasis in the cell, contributing to its ability to limit
multiple viruses; however, further work will need to be
performed to investigate this in multiple viral systems
and to characterize its ability to bind VAP-A and the
downstream consequences of this interaction.Concluding Remarks
Since its discovery as an interferon-induced gene
and the identification of its role as a potent host
antiviral protein against HCMV in 2001, there has
been significant advances in our understanding of
this unique host protein regarding its regulation, its
antiviral properties and its ability to modulate innate
immune signaling. However, the majority of studies
have investigated its antiviral function and it is now
clear that viperin is a genuine host antiviral protein.
Even more intriguing about this protein is its promis-
cuous nature by which it seems to exert its antiviral
effect. Viperin appears to use a variety of different
antiviral mechanisms from interacting directly with
viral and host proteins essential for viral replication to
interaction with host organelles such as the ER, lipid
droplets and mitochondria. In an interesting twist from
its described antiviral activities, and perhaps further
reiterating its ancient origin, it has also recently been
shown to play a positive role in HCMV replication and
furthermore can modulate type I IFN production in
pDCs via modulating signaling from TLR7 and TLR9.
Thus, it seems that viperinmay impact viral replication
via both direct and indirect mechanisms, which raises
the question of how one protein can have such a
diverse array of functions and possess antiviral
activity to a vast array of viruses using a variety of
antiviral mechanisms. Clearly, more investigation into
this mysterious protein is warranted to fully elucidate
its functional characteristics not only in its role as an
antiviral but also in its emerging role in innate immune
control of viral infection.
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ISG, interferon-stimulated gene; HCMV, human cytome-
galovirus; ER, endoplasmic reticulum; HIV, human im-
munodeficiency virus; HCV, hepatitis C virus; DENV,
dengue virus; dsRNA, double-stranded RNA; ISGF3, ISG
factor 3; JEV, Japanese encephalitis virus; CHIKV,Chikungunya virus; MDM, monocyte-derived
macrophage; WNV, West Nile virus; RC, replication
complex; VAP-A, vesicle-associated membrane
protein-associated protein-A; IFV, influenza virus; WT,
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